CAFERGOT
LOE ApproachingNDARECTALSUPPOSITORYPriority Review
Approved
Apr 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CAFERGOT by Novartis is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. First approved in 1953.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAFERGOT is a fixed-dose combination of ergotamine and caffeine administered as a rectal suppository for acute migraine treatment. Ergotamine acts as an alpha-adrenergic blocker with direct vasoconstrictive effects on cranial blood vessels, while caffeine enhances this effect; the rectal route allows direct access to cranial vasculature, bypassing hepatic metabolism and accommodating patients with nausea/vomiting. This formulation has been the standard acute migraine therapy for decades, particularly for patients unable to tolerate oral medications.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting stable but shrinking team investment and transition focus toward legacy product management.
Mechanism of Action
CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CAFERGOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.